The HES1 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population with targeted disruption of the HES1 gene. This heterogeneous pool provides a robust loss-of-function model for studying HES1-dependent signaling in a human liver adenocarcinoma background. The polyclonal format offers functional knockout across a diverse allelic spectrum without single-cell clone isolation, avoiding clonal artifacts and better representing cellular heterogeneity.
SK-HEP-1 is a human liver adenocarcinoma cell line isolated from ascites, displaying both epithelial and endothelial features. This duality makes it an effective model for investigating tumor plasticity, metastasis, and angiogenic signaling in hepatocellular carcinoma. The line expresses components of Notch, Wnt, and Hedgehog pathways, establishing a physiologically relevant context for dissecting HES1-mediated transcriptional regulation.
HES1 is a basic helix-loop-helix transcriptional repressor and a critical downstream mediator of Notch signaling. Upon ligand engagement of Notch receptors (NOTCH1-4), ??-secretase releases the Notch intracellular domain (NICD), which translocates to the nucleus and forms a complex with CSL/RBP-J and MAML to activate HES1 transcription. HES1 represses target genes by binding N-box/E-box elements and recruiting TLE/Groucho corepressors and HDAC1. Additional regulatory inputs from Wnt/??-catenin and Hedgehog/GLI pathways converge on HES1 expression. Downstream repression targets include the CDK inhibitors p21/CDKN1A and p27/CDKN1B, the proneural factor ASCL1/Mash1, and Cyclin D1, with HES1 also subject to auto-repression, creating oscillatory dynamics that control cell fate decisions.
In SK-HEP-1 cells, HES1 promotes cancer stemness, epithelial-mesenchymal transition (EMT), and proliferation. Knockout of HES1 disrupts these oncogenic programs, enabling detailed dissection of Notch-driven tumorigenic mechanisms in hepatic cancer. The polyclonal population mimics intratumoral heterogeneity, making it suitable for pooled screening approaches and competitive assays where mixed genotypes reveal selective pressures and fitness effects in the absence of HES1 activity.
Key applications include investigating the Notch/HES1 axis in hepatocellular carcinoma progression, drug screening for Notch inhibitors, and functional genomics of bHLH repressors. Researchers can employ Western blotting, RT-qPCR of downstream targets, ChIP-qPCR for HES1 promoter occupancy, and functional assays such as MTT proliferation, Annexin V apoptosis, and Transwell migration. Notch-responsive luciferase reporter assays and immunofluorescence are also routinely used. For inquiries regarding this product, please contact Ascent Research.
